Oval Medical CEO to participate in Industry Roundtable at Annual Meeting of the Controlled Release Society

Oval Medical’s CEO, Ms Barbara Lead will be one of the panellists in the Industry Roundtable “Drugs, Delivery, and Patients – How Will We Bring It All Together in the New World?” at the Annual Meeting of the Controlled Release Society on Sunday July 26th. The panel discussion, moderated by Ms Debra Bingham (Partner at […]

Continue Reading

Oval Medical represented at Conferences and Events

Oval Medical’s partner Solize Corporation will exhibit and present at the InnoPack 2015 conference in Tokyo (April 22-24th) in conjunction with the CPhI event held at TokyoBigSight. Representatives from Oval and Solize will be present to demonstrate the Oval autoinjectors and collaboration opportunities. Oval Medical has been attending and exhibiting at a number of conferences […]

Continue Reading

Completion of Innovate UK Smart Award

April 2015 Oval Medical completes Innovate UK (formerly The Technology Strategy Board) Smart Award Grant for development of manufacturing equipment for their novel container closure system. Oval Medical has developed bespoke sealing equipment for the drug container in collaboration with 3P Limited; this is a key manufacturing step for its leading edge auto injector. Commenting […]

Continue Reading

Rights Issue

March 2015 Oval Medical recently completed a £1.5m rights issue for the development of the manufacturing process for its novel autoinjector. The autoinjector facilitates the delivery of the new generation of biologics by eliminating issues including glass breakage, drug contamination and variable injection times. This equipment will form part of the manufacturing process for clinical […]

Continue Reading

Oval Medical awarded Innovate UK Proof of Market funding award

November 2014 Oval Medical received £25,000 to contribute to market research for its new, innovative epinephrine autoinjector for the treatment of anaphylactic shock. The incidence of allergies that can cause this serious and potentially fatal reaction is growing worldwide. Oval’s epinephrine autoinjector incorporates the same design philosophy as the first device being used for sumatriptan. […]

Continue Reading

Oval and SOLIZE enter into collaboration on injection device development

Press Release For Immediate Release Cambridge, UK. Monday, 28 April 2014 – Oval Medical Technologies Limited (“Oval”) Oval and SOLIZE enter into collaboration on injection device development. Working together to accelerate product development in the growing auto-injector market. Oval Medical Technologies Ltd (Cambridge, UK) and SOLIZE Corporation (Tokyo, Japan) have agreed to collaborate together in […]

Continue Reading

Technology Strategy Board – Smart Funding Award

Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]

Continue Reading

Oval Medical secures £1 million deal with US pharmaceutical company

Oval Medical Technologies Ltd (‘Oval’) today announced that they have signed another deal following an initial feasibility study with a global pharmaceutical company, to a value in excess of one million pounds. The feasibility study, which primarily focused on the pharmaceutical drug’s stability in Oval’s standard primary drug container, started in March 2012 and completed […]

Continue Reading

Oval Medical appoints new CEO

The board of Oval Medical Technologies Limited (‘Oval’) announces that effective from 1st May 2013, Barbara Lead has succeeded Dr Catherine Beech as Chief Executive Officer of Oval Medical Technologies Limited. Catherine was instrumental in establishing Oval with Matthew Young in late 2009 and completing the initial Angel financing in early 2010. Since then, with […]

Continue Reading